Diagnostics solutions for pregnancy care

Helping improve the lives of women and the baby

womens-health-ultrasound

A simple blood test can now deliver clear, reliable results to help identifying patients at risk for potentially life threatening complications.

Women’s health is an emerging topic on the agenda of many health organizations and authorities worldwide. The standard of medical care for women has been improving, thanks to the availability of new technologies and the increased interest taken by the public and by healthcare authorities.

Roche is investing increasing sums in women’s health and is developing innovative diagnostic solutions for a wide range of diseases including infectious diseases, as well as for oncology and maternal care. By focusing on unmet medical needs, Roche has been able to provide reliable and medically differentiated products in the field of pregnancy care to help improve the lives of women and newborns.

  • With Elecsys® TORCH testing we are offering a portfolio of assays that help healthcare professionals monitor infants and pregnant women for congenital, perinatal and neonatal infections 
  • Our Elecsys assays for first trimester screening of pregnant women enable healthcare professionals to use a non-invasive biochemical testing approach limiting the number of unnecessary invasive procedure such as amniocentesis 
  • The Elecsys sFlt-1/PlGF ratio is an easy-to-use blood test which aids physicians in diagnosing preeclampsia, helping them make decisions about appropriate clinical management and enabling timely intervention supporting the mother and unborn child

Preeclampsia – a leading cause of fetal and maternal death

Preeclampsia affects about one in 20 pregnancies and is one of the leading causes of maternal death. It can be life-threatening for mother and baby, especially if diagnosed late, and is an indication for immediate preterm delivery when acute. However, in line with current guidelines that have remained unchanged for decades, the diagnosis of preeclampsia is still based on the clinical parameters of hypertension and proteinuria, which are neither specific nor sensitive. With the Elecsys® sFlt-1 and Elecsys PlGF immunoassays a simple blood test can now deliver clear, reliable results to help identifying patients at risk for potentially life threatening complications.

In 2010 Roche opened the PROGNOSIS1 study, which is expected to mark a significant improvement in the short-term prediction of preeclampsia. PROGNOSIS is investigating the correlation between the ratio of the proteins sFlt-1 and PlGF in maternal blood and the risk of developing preeclampsia over the subsequent four weeks.

“PROGNOSIS has a study design that is unseen in the last 20 years of preeclampsia research.“

Annetine Staff, Professor of the Department of Gynaecology at the Women and Childrens Division at Oslo University and PROGNOSIS principal coordinating investigator.

Such a predictive test would enable healthcare professionals to focus on patients with the greatest need of appropriate and timely clinical intervention before the development of full-blown preeclampsia. Likewise, patients identified as unlikely to develop the disease can be safely discharged from hospital. Roche expects first study results to be reported this year.

Reference

1) in full: Prediction of short-term outcome in pregnant women with suspected preeclampsia study

2) Not available in the U.S.